Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Xiamen Amoytop Biotech Co., Ltd.

Clinicaltrial registered26 Oct 2026

Xiamen Amoytop Biotech Co., Ltd.

26 Oct 2026: Trial registered · A Clinical Study of Long-Term Administration of Inpegsomatropin Injection in Participants With Idiopathic Short Stature Who Have Completed Phase Ⅲ Clinical Trials. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
26 Oct 2026
Title
A Clinical Study of Long-Term Administration of Inpegsomatropin Injection in Participants With Idiopathic Short Stature Who Have Completed Phase Ⅲ Clinical Trials
Conditions
Idiopathic Short Stature
Phase
Not applicable
Study Type
Interventional
Status
Recruiting
Countries
China
Country
China
Reference
NCT07894341
Location
China
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Xiamen Amoytop Biotech Co., Ltd.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Xiamen Amoytop Biotech Co., Ltd. in our registers.

More from China

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.